Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
psoriasis
Biotech
J&J, Protagonist's oral psoriasis prospect scores in phase 3s
The phase 3 successes pad the IL-23 blocker's case as J&J prepares to prove its worth against BMS' oral psoriasis treatment Sotyktu.
Zoey Becker
Nov 19, 2024 11:44am
Lilly changes lead psoriasis program from $2.4B Dice buyout
Oct 30, 2024 10:00am
Awaiting regulator verdict, Innovent posts latest psoriasis win
Oct 29, 2024 9:50am
InnoCare's TYK2 inhibitor holds its own in ph. 2 psoriasis trial
Oct 9, 2024 9:10am
Ventyx's last hope for inflammatory med ends in Crohn's failure
Jul 29, 2024 9:45am
Alumis downsizes IPO, tacks on private placement
Jun 28, 2024 5:02am
